Results of the Antibody Mediated Prevention (AMP) studies to be presented at the IAS HIV Research for Prevention (HIVR4P
// Virtual) conference.
Tuesday, 26 January, 2021 (Geneva, Switzerland) — IAS – the International AIDS Society – welcomes new results from two proof-of-concept studies (HVTN 704/HPTN 085 and
HVTN 703/HPTN 081- the AMP Studies) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody
(bNAb) VRC01 can prevent some HIV infections.
Results of the study were discussed in a press conference today prior to the opening of the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), and will be reviewed in more detail in two HIVR4P conference presentations on Wednesday 27 January at 15.00 UTC and Thursday 4 February at 17.30 UTC.
The AMP results include data from more than 4,600 participants in two studies that enrolled HIV-negative men and
transgender people who have sex with men in the U.S., Brazil and Peru (HVTN 704/HPTN 085) and HIV-negative cisgender
women in sub-Saharan Africa (HVTN 703/HPTN 081).
The studies build off of traditional concepts of vaccination, in which a vaccine primes the immune system to make
antibodies that can neutralize an infectious agent such as HIV. Instead of priming recipients to create antibodies, the
AMP study infused participants with an antibody called VRC01, or a placebo, at eight-week intervals over 80 weeks. With
this approach, known as passive immunization, AMP participants who received the antibody were 75 per cent less likely to
become infected with a strain of HIV that had been shown to be sensitive to VRC01 in in vitro studies. Importantly, however, the AMP studies also found that VRC01 was not protective against many strains of the
virus. The study findings support the need for additional research on infusions with multiple antibodies capable of
achieving broader protection against a variety of HIV strains.
“AMP is an exciting proof-of-concept of a new and innovative potential form of HIV prevention,” said Adeeba Kamarulzaman, President of the IAS. “These studies open an important door to what may one day become yet another important approach
to preventing HIV infection.”
“Like most innovative research studies, AMP produced complex results that also raise important new questions for
researchers,” said Roger Tatoud, Deputy Director of HIV Programmes and Advocacy at IAS and head of the IAS’s Global HIV Vaccine Enterprise. “Moving
forward, the field must consider the dual challenges of developing cocktails of antibodies that are both more broadly
effective and more easily and practically delivered, while remaining affordable and accessible.”
To help address those questions, the IAS will host an upcoming series of webinars with AMP study investigators to
explore the results of these studies and their implications for future development of passive immunization approaches.
Registration for the HIVR4P // Virtual conference (26 & 27 January and 3 & 4 February), which includes presentation of the AMP results along with the latest research on antibody-mediated
prevention, HIV vaccines, pre-exposure prophylaxis, treatment as prevention and new and emerging forms of prevention is
available at: https://www.hivr4p.org/registration/
“AMP was a well-conducted study with excellent participant safety and retention,” said Susan Buchbinder, Chair of the IAS’s Global HIV Vaccine Enterprise Advisory Group. “We congratulate everyone involved, and in particular
the study volunteers and team, who have made a vital contribution to HIV prevention research. With 1.7 million new HIV
infections last year, HIV remains an enormous global health crisis that requires multiple prevention options. AMP
demonstrates both the importance and the value of maintaining a strong, ongoing commitment to HIV prevention research.”
Additional Enterprise materials on both of the AMP studies and on Passive Immunization are available at https://vaccineenterprise.org/More information about the study
The AMP (Antibody Mediated Prevention) Studies are conducted by the HIV Vaccine Trials Network and the HIV Prevention
Trials Network (HPTN) and sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
For further information on (HVTN 704/HPTN 085) please see https://clinicaltrials.gov/ct2/show/NCT02716675?term=hvtn704=2=1
For further information on (HVTN 703/HPTN 081) please see https://clinicaltrials.gov/ct2/show/NCT02568215?term=hvtn703=2=1